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Abstract
Inhibition or blockade of myostatin, a negative growth factor of skeletal muscle, enhances muscle growth and
therefore is considered a promising strategy for the treatment of muscle-wasting diseases such as the muscular
dystrophies. Previously, we showed that myostatin blockade in both normal and dystrophin-deficient mdx mice
by systemic delivery of the myostatin propeptide (MPRO) gene by an adeno-associated virus serotype 8 (AAV8)
vector could enhance muscle growth and ameliorate dystrophic lesions. Here, we further investigate whether the
muscle growth effect of myostatin blockade can be achieved in dogs by gene transfer. First, we cloned the canine
MPRO gene, packaged it in the AAV8 vector, and showed robust muscle-enhancing effects after systemic
delivery into neonatal mice. This vector was then further tested in two 3-month-old normal dogs (weighing 9.7
and 6.3 kg). The vector was delivered to one limb by hydrodynamic vein injection, and the contralateral limb
served as a control. The delivery procedure was safe, without discernible adverse effects. AAV vector DNA and
MPRO gene expression were detected by quantitative polymerase chain reaction, Western blotting, and im-
munofluorescence staining of muscle biopsies. Overexpression of MPRO resulted in enhanced muscle growth
without a cytotoxic T lymphocytic immune response, as evidenced by larger myofibers in multiple muscles,
increased muscle volume determined by magnetic resonance imaging, and the lack of CD4+ and CD8+ T cell
infiltration in the vector-injected limbs. Our preliminary study thus supports further investigation of this ther-
apeutic strategy in the dystrophin-deficient golden retriever muscular dystrophy dog model.
Introduction
Among the genetic muscle degenerative diseases, Du-chenne muscular dystrophy (DMD) is the most common
and lethal form, afflicting 1 of every 3500 males. DMD is
characterized by progressive muscle weakness and degener-
ation that often leads to severe respiratory or cardiac disease
in the patient’s late teens and early twenties (Hoffman et al.,
1996). DMD is caused by recessive mutations in the dystro-
phin gene. The absence of functional dystrophin results in loss
of the dystrophin-associated protein complex and causes in-
stability of the myofiber plasma membrane (Hoffman et al.,
1987; Koenig and Kunkel, 1990). These deficiencies, in turn,
lead to chronic muscle damage and degeneration. Because of
the lack of an effective treatment, novel therapeutic ap-
proaches are being explored (Wang et al., 2000).
Myostatin, also known as growth=differentiation factor-8
(GDF8), is a member of the transforming growth factor (TGF )-
b superfamily (McPherron et al., 1997). Numerous studies
have demonstrated that myostatin is a negative regulator of
skeletal muscle growth. Like other TGF-b family members,
myostatin is synthesized as a precursor protein that under-
goes proteolytic processing at a dibasic site to generate an
N-terminal propeptide, termed myostatin propeptide (MPRO),
and a disulfide-linked C-terminal dimer, the biologically ac-
tive part (for detailed review see Lee, 2004). On cleavage, the
mature myostatin C-terminal dimer still remains associated
with its inhibitor MPRO in a latent complex. Additional in-
hibitors of mature myostatin include follistatin (Hill et al.,
2002), the follistatin-related gene (FLRG), growth and differ-
entiation factor-associated serum protein-1 (GASP-1) (Hill
et al., 2002), and so on. Both myostatin gene knockout mice
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(McPherron et al., 1997; Tobin and Celeste, 2005) and trans-
genic mice expressing higher levels of myostatin inhibitors
(Zhu et al., 2000; Lee and McPherron, 2001) show significant
increases in skeletal muscle mass. Furthermore, mutations in
the myostatin gene in cattle result in a double-muscling
phenotype (McPherron and Lee, 1997). Downregulation of
myostatin gene expression in Texel sheep (Clop et al., 2006)
caused muscle hypertrophy, as well. In another report, partial
loss of myostatin in heterozygous whippet racing dogs re-
sulted in faster running speed, whereas the homozygous
whippet dogs were muscular (Mosher et al., 2007). Im-
portantly, a mutation in humans was identified in a healthy
child who showed muscle hypertrophy and unusual strength
(Schuelke et al., 2004).
The biological function of myostatin has raised the possi-
bility of using inhibitors to promote muscle growth and im-
prove the disease phenotypes in a variety of primary and
secondary myopathies, including the muscular dystrophies
(Lee, 2004). In a proof-of-principle study, Wagner and co-
workers (2002) bred myostatin null mutant mice with mdx
mice and showed improved muscle regeneration in mdx mice
lacking myostatin. Administration of a myostatin-blocking
antibody increased muscle strength and decreased muscle
degeneration in mdx mice (Bogdanovich et al., 2002). Similar
results were seen when a purified myostatin propeptide was
injected (Bogdanovich et al., 2005). Bartoli and coworkers also
reported that adeno-associated virus (AAV)-mediated
myostatin propeptide ameliorated limb girdle muscular
dystrophy in calpain-3-deficient (LGMD2A) mice (Bartoli
et al., 2007). Most recently, Wagner’s group has shown that
inhibition of fibrosis in dystrophic muscle contributes to the
benefits of myostatin blockade (Li et al., 2008).
In our previous studies, we have investigated the effect of
myostatin inhibition in normal C57BL=6 mice and dystrophin-
deficient mdx mice by delivering AAV vector encoding the
mouse MPRO gene. We observed a significant increase in
skeletal muscle mass after systemic delivery of AAV8-MPRO-
Ig vector into normal mice (Qiao et al., 2008). In addition, we
noticed significantly increased skeletal muscle mass, together
with more uniform myofiber size, and less mononuclear cell
infiltration and fibrosis after tail vein injection into mdx mice
(Qiao et al., 2008). Because the small rodent mdx mouse model
has a mild phenotype and near-normal life span, alternative
animal modes have been actively explored. A well-studied
large animal model of DMD is the golden retriever muscular
dystrophy (GRMD) dog. The GRMD model displays remark-
able clinical and pathological similarities to its human homolog
(Cooper et al., 1988; Shimatsu et al., 2003, 2005), and has been
increasingly used as a large animal model of DMD to evaluate
the efficacy of both gene and cell therapy. The current study
was designed to test whether the muscle growth-enhancing
effect of myostatin blockade could be achieved with a similar
strategy in normal dogs, and therefore pave the way for future
studies in GRMD dogs.
Materials and Methods
Construction of pAAV-cMPRO-Fc plasmid
and AAV vector production
The canine myostatin propeptide (cMPRO) cDNA (gene
accession number NM_001002959) was generated by reverse
transcription-polymerase chain reaction (PCR) from normal
dog muscle tissue. The dog IgG Fc domain (gene accession
number AF354264) was also generated by reverse transcrip-
tion PCR from a dog spleen cDNA library. The forward and
reverse primers used for cMPRO were AGCCACCATGCA
GAGACTGCAAATCT and tttcatcttctggatctttttggtgtg, respec-
tively. The primers for amplification of the dog IgG Fc domain
were dog_IgG_L (cacaccttcccgtccgtcc) and dog_IgG_R (tgcttta
tttcatgatgggtgcc). The dog MPRO cDNA and Fc domain were
spliced together by the PCR method, and the final product was
cloned into an AAV plasmid driven by the chicken b-actin
(CAG) promoter including cytomegalovirus (CMV) enhancers
and a large synthetic intron (Kootstra et al., 2003). The final
constructions were sequenced for verification.
The recombinant viral vector stocks were produced ac-
cording to the three-plasmid cotransfection method (Xiao
et al., 1998). The viral particles were purified twice by CsCl
density gradient ultracentrifugation, using the previously
published protocol (Qiao et al., 2005). Vector titers, or viral
particle numbers, were determined by the DNA dot-blot
method and were in the range of 21012 to 51012 vector
genomes (VG)=ml.
Hydrodynamic limb vein injection of AAV
in normal dog limbs
The experimental protocols involving the animals have
been approved by the IACUC committee of the University of
North Carolina at Chapel Hill (UNC-CH) and are in compli-
ance with all required regulations. Two 3-month-old normal
male dogs were used in the hydrodynamic limb vein injection
experiments with AAV8-cMPRO-Fc vector. The dogs were
first induced by intramuscular administration of atropine
sulfate (0.04 mg=kg body weight) and butorphanol tartrate
(0.4 mg=kg) and then intubated and maintained with 1–2%
sevoflurane. All vital signs were closely monitored through-
out the procedure. The limbs to be injected were shaved and
scrubbed with Betadine (povidone-iodine) and 70% isopropyl
alcohol. A catheter was inserted into the saphenous vein and
secured with tape. For pelvic limb injection, a rubber tourni-
quet was wrapped tightly around the proximal limb at the
level of the inguinal area. For thoracic injection, the catheter
was placed in the cephalic vein and the tourniquet was
wrapped tightly around the proximal limb in the axillary
space. The AAV vector dose was 11013 VG=kg body weight
for pelvic limb injection and 31012 VG=kg body weight for
thoracic limb injection. The vector injection volume was
20 ml=kg for the pelvic limb and 12 ml=kg for the thoracic
limb. The injection speed was 1 ml=sec for both limbs and was
controlled with a syringe pump (model PHD 2000; Harvard
Apparatus, Holliston, MA). The total occlusion time was
10 min starting from the beginning of injection. Muscle biop-
sies of both injected and contralateral limbs were performed
3 months after AAV injection.
Immunofluorescence staining
and morphometric analysis
Rat monoclonal anti-laminin b2-chain antibody (diluted
1:3000; Chemicon=Millipore, Bedford, MA) was used to dis-
play the circumferences of the myofibers. Cryo-thin sections
of biopsied muscle from treated and control limbs were ap-
plied for laminin staining. For morphometric analysis, pic-
tures were taken and the radii of myofibers were analyzed
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with MetaMorph software (Molecular Devices, Downing-
town, PA), with a minimum of 600 myofibers from each
sample.
Real-time PCR analysis
A TaqMan assay was designed for real-time PCR analysis.
In brief, the total DNA of muscle tissue was extracted with a
QIAamp DNA mini kit (cat. no. 51304; Qiagen, Valencia, CA),
and the total RNA was purified with TRIzol reagent (cat. no.
15596-018; Invitrogen, Carlsbad, CA). The reverse transcrip-
tion reaction was done with a high-capacity cDNA reverse
transcription kit (part 4368814; Applied Biosystems, Foster
City, CA). The primers and probe for vector DNA-based real-
time PCR were as follows: cmv-forward, gta tgt tcc cat agt aac
gcc aat ag; cmv-reverse, ggc gta ctt ggc ata tga tac act; cmv
probe, FAM-TCA ATG GGT GGA GTA TTT A-MGB. The
primers and probe for mRNA quantification were as follows:
RT-CAG-F, tct gac tga ccg cgt tac tc; RT-CAG-R, ccg cgg tgg
agc tca ag; Cag probe, FAM-TCA ATG GGT GGA GTA TTT
A. All the real-time PCRs were performed on a 7300 real-time
PCR system (Applied Biosystems) according to the manu-
facturer’s instructions.
Enzyme-linked immunosorbent assay analysis
The enzyme-linked immunosorbent assay (ELISA) method
was developed to detect the cMPRO–Fc fusion protein but not
the endogenous myostatin propeptide. First, a clear 96-well
plate was coated with anti-mouse antibody (diluted 1:500)
overnight at 48C. Second, the plate was incubated with anti-
dog MPRO polyclonal antibody (diluted 1:1000; generated
from mice by the laboratory of X. Xiao, UNC-CH) for 0.5 hr at
room temperature. We did not directly coat the plate with the
anti-dog MPRO antibody because this antibody was un-
purified; coating unpurified protein would induce undesired
high background. Third, the plate was blocked with 1% milk
for 2–6 hr at room temperature. The fourth step was to in-
cubate with antigen (tissue or sera containing MPRO–Fc, or
purified cMPRO–Fc protein from plasmid-transfected con-
ditional medium). The plate was then incubated with anti-
dog Fc–horseradish peroxidase (HRP) conjugate (cat. no.
30371, diluted 1:20,000; Alpha Diagnostic International, San
Antonio, TX) followed by color development. In the data
analysis part, the optical density (OD) readings from tissues
and sera were blanked with normal uninjected dog muscle
tissue and normal uninjected dog serum, respectively. The
ELISA ensemble kit was purchased from Alpha Diagnostic
International.
Magnetic resonance imaging analysis
Magnetic resonance imaging (MRI) studies were done with
a Siemens 3-T Allegra head-only system (Siemens Medical
Solutions, Malvern, PA) at the UNC-CH Animal Imaging
Center. T2-weighted images with and without fat saturation
were completed. Proximal and distal limbs were imaged
separately. Image analysis was done through the UNC-CH
Neuro Image Analysis Laboratory, using the software pro-
gram ITK-SNAP (www.itksnap.org).1 We completed region-
of-interest volumetric quantitative measurements of the
muscle cross-sectional area (mm3) in both pelvic limbs from
each dog at the level of the mid-femur and the proximal and
distal tibia (see Fig. 4c). A total of five consecutive 1-mm im-
ages were segmented. The measurements varied among the
different levels and muscles, with no consistent differences
(Yushkevich et al., 2006).
Results
Test of biological function of AAV8-cMPRO-Fc
vector in mice
To avoid an immune response against the mouse MPRO–Fc
in dogs, we cloned canine myostatin propeptide cDNA by
PCR and fused it with the canine IgG Fc domain to prolong its
half-life in vivo (see Materials and Methods for details)
(Wolfman et al., 2003; Qiao et al., 2008). Similar to our previous
study, we used a CAG promoter (consisting of the CMV en-
hancer, chicken b-actin promoter, and a globin intron) to drive
the myostatin propeptide gene for robust and long-term ex-
pression in vivo (Qiao et al., 2008). Before performing experi-
ments in dogs, we tested whether the cMPRO–Fc vector is
functional in mice. AAV8-cMPRO-Fc vector was delivered
into neonatal ICR mice by intraperitoneal injection to mini-
mize humoral immune responses to the dog protein. The
AAV-treated mice and untreated littermates were weighed
periodically for body weight gain. As shown in Fig. 1a, the
treated mice had significant weight gain (22.7 1.16 g for fe-
males) over the untreated littermates (20.4 0.49 g for fe-
males) at 4 weeks, when the mice were weaned. At 7 weeks of
age, the average body weight of treated mice (33.7 2.3 g
for females) increased by more than 30% over the untreated
littermates (27 1.5 g for females). The AAV8-cMPRO-Fc
vector-treated mice also appeared heavier and more muscular
(Fig. 1b). Histological examination revealed that muscle fiber
sizes of treated mice were essentially doubled (Fig. 1c). These
data clearly indicated that the AAV-cMPRO-Fc vector was
functional in mice.
Detection of vector DNA and MPRO–Fc mRNA
expression in dog limbs after hydrodynamic
limb vein injection
We next proceeded to the experiments in dogs. To deliver
the AAV vector into multiple muscles, we used the hydro-
dynamic limb vein (HLV) delivery method, which rapidly
delivers a solution containing nucleic acids or viral vectors into
a limb that is blocked by a tourniquet during injection (Arruda
et al., 2005; Herweijer and Wolff, 2007). We chose to use AAV8
as the vector, because it is able to cross blood vessel barriers
and transduce skeletal muscles efficiently via systemic deliv-
ery (Wang et al., 2005). Two normal dogs were used in this
study. Dog Ramone (6.3 kg) had the AAV vector injected in the
pelvic limb, whereas dog Link (9.7 kg) had the vector injected
in the thoracic limb, both by the HLV injection method. The
AAV8-cMPRO-Fc vector dose was 11013 VG=kg body
weight for Ramone, and 31012 VG=kg body weight for Link.
A lower vector dose was used in Link because of the smaller
size of the thoracic versus pelvic limbs. A rubber tourniquet
was used to block venous return at the level of the inguinal
and axillary areas for 10 min during vector injection. No pro-
cedure- or vector-related adverse events were observed dur-
ing or after vector injection.
Three months after vector delivery, biopsy was per-
formed on various muscles of both injected limbs and the
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contralateral control limbs. Quantitative PCR of total DNA
from each muscle biopsy showed that AAV vector copy
numbers (CAG promoter as the target sequence) in the in-
jected pelvic limb of dog Ramone were consistently higher
than in the uninjected contralateral pelvic limb in all five pairs
of biopsy samples (Fig. 2a). However, the copy numbers on a
per-diploid genome basis (or per nucleus for muscle myofi-
bers) were not high. Specifically, the gastrocnemius (lower
limb) and vastus lateralis and biceps femoris (upper limb)
muscles had 1.2 to 1.55 copies per nucleus, whereas the long
digital extensor (lower limb) and cranial sartorius (upper
limb) had 0.08 to 0.25 copy per nucleus (Fig. 2a). cMPRO–Fc
mRNA expression was determined by quantitative real-time
(RT)-PCR. The profiles were in general agreement with the
vector DNA copy numbers. Thus, higher mRNA levels were
found in muscle samples with higher vector DNA copy
numbers (Fig. 2b). Because quantitative RT-PCR detected the
chicken b-globin exon–intron sequence, a part of the CAG
promoter in the cMPRO–Fc expression cassette, the data re-
flected only the levels of cMPRO mRNA derived from the
vector DNA, not from the endogenous cMPRO gene. The
lower RT-PCR signals detected in the contralateral muscles
might have resulted from cMPRO–Fc vector that dissemi-
nated systemically from the injected limb.
Detection of cMPRO–Fc protein in
injected muscles and sera
We next wished to confirm vector gene expression by ex-
amining the cMPRO–Fc protein product in muscle and sera.
Western blotting of muscle biopsy samples from Ramone
showed cMPRO–Fc of the expected molecular weight in the
AAV-treated limb (Fig. 3a) in the three muscles that had
higher vector DNA copy numbers and mRNA levels (Fig. 2a
and b). The presence of cMPRO–Fc protein was also con-
firmed by immunofluorescence staining of gastrocnemius and
other muscles (Fig. 3b). Furthermore, quantitative ELISA
analysis of serum samples detected cMPRO–Fc protein in dog
Ramone as early as 1 week after vector injection and the
concentration slightly declined over the course of 4 weeks
(Fig. 3c). The serum cMPRO–Fc levels were, however, more
than an order of magnitude lower than those of muscle (data
not shown). Together, the preceding data showed that
cMPRO–Fc gene expression was successfully achieved in
multiple muscles after HLV injection.
Enhanced muscle growth resulting
from cMPRO–Fc expression
Earlier in this study, we observed an increase in muscle
myofiber size by overexpression of cMPRO–Fc in mice.
Here, we wished to determine whether cMPRO–Fc expres-
sion could also enhance growth of dog muscles. Hema-
toxylin and eosin (H&E) staining was performed on the
AAV-treated and untreated limbs to determine myofiber
sizes. The myofiber diameters of gastrocnemius and biceps
femoris muscles of dog Ramone showed the most significant
increases in treated limb relative to untreated limb (Fig. 3a).
This was further confirmed by quantitative analysis of a
large number of myofibers by digital morphometric analyses
FIG. 1. Muscle growth-enhancing effects of AAV-cMPRO-Fc in mice. The AAV8-cMPRO-Fc vector was delivered into neo-
natal ICR mice by intraperitoneal injection. There were seven mice for each group. (a) Growth curve of the mice. *p< 0.05;
**p< 0.01. (b) Photograph of skinned AAV8-cMPRO-Fc-treated mouse versus control mouse. The mice were 7 weeks old when
the picture was taken. Note that the treated mouse is more muscular than the control. (c) Hematoxylin and eosin (H&E) staining
of treated versus control quadriceps muscle. Both pictures were taken at the same magnification. Treated muscle fiber appeared
bigger compared with control muscle fiber. Scale bars: 100mm.
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(Fig. 3b). However, the myofiber sizes in the remaining three
muscles including vastus lateralis, which had good expres-
sion of the cMPRO–Fc gene, did not show significant differ-
ences between vector-treated and untreated limbs (Fig. 3b).
The reason remains unclear and is discussed later. We also
examined the myofiber sizes of biopsies taken from dog Link,
who received vector injection via a thoracic limb. Only the
extensor carpi radialis muscle showed significant myofiber
size increase in the vector-treated limb (Fig. 4a). This muscle
also had a higher vector DNA copy number and higher
cMPRO mRNA level than the other two muscle groups, the
triceps brachii and common digital extensor (Fig. 2c and d).
This result is consistent with the degree of transgene expres-
sion.
Finally, we performed MRI on perfused versus non-
perfused limbs of dog Ramone to examine whether muscle
volume was enlarged after vector delivery. Similar to the re-
sults obtained in morphometric analyses, we observed muscle
volume increase in some muscles, but not in all the muscles.
For example, muscle volume in the mid-femur segment of the
vector-perfused limb was slightly higher than that of the
nonperfused limb (27,061 vs. 25,380 mm3) (Fig. 4c). In the tibia
middle segment, the muscle volume of the perfused limb was
also slightly increased compared with that of the nonperfused
limb ((3051 vs. 2653 mm3) (Fig. 4c). However, in the tibia
proximal segment, there was no difference in muscle volume
between the perfused limb and nonperfused limb (6190 vs.
6112 mm3) (Fig. 4c).
Discussion
Inhibition or blockade of myostatin to promote muscle
growth has been explored as a potential treatment for muscle-
wasting diseases, including sarcopenia, cachexia, and mus-
cular dystrophies (Bogdanovich et al., 2002, 2005; Lee et al.,
2005; Tobin and Celeste, 2005; Ohsawa et al., 2006; Bartoli et al.,
2007; Wagner et al., 2008). Here, we investigated the muscle
growth effect of myostatin inhibition by gene delivery of a
natural inhibitor of myostatin, the myostatin propeptide, in
normal dogs. To achieve broad transgene expression in the
limb muscles, the hydrodynamic limb vein perfusion tech-
nique and AAV8 vector were used. We have shown the first
evidence that somatic gene transfer of cMPRO–Fc gene in
dogs can enhance growth in multiple muscle groups, as evi-
denced by increased myofiber sizes, similar to the results
obtained in previous mouse studies (Qiao et al., 2008). No
vector-related adverse effects, including cellular immune re-
sponses after gene transfer, were observed. This study sup-
ports future investigation of this therapeutic strategy in
dystrophin-deficient dogs.
Although cMPRO–Fc expression enhanced growth of mul-

























































































































































































































FIG. 2. Real-time PCR analysis of vector DNA and transgene mRNA. Three months after vector delivery, biopsy was
performed on treated and control legs. (a) Real-time PCR analysis for vector DNA copy numbers in dog Ramone. AAV8-
cMPRO-Fc vectors were most numerous in skeletal muscle from treated leg (blue columns), but some were present in control leg
muscle (red columns). (b) Real-time PCR for quantification of cMPRO mRNA in dog Ramone. There is a 100- to 10,000-fold
difference in transgene expression in mRNA level between treated (blue columns) and control legs (red columns). (c) Real-time
PCR assay for vector DNA copy numbers in dog Link. Red columns, control leg data; blue columns, treated leg data. (d) Real-
time PCR for cMPRO cDNA quantification of dog Link.
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showed myofiber size increase. A plausible explanation is
that the relatively low vector copy numbers in those muscles
may have produced insufficient gene expression. The vector
doses in the dogs were more than 10 times lower than in mice,
if the doses were based on the weight of targeted tissues
(51011 VG=neonatal mouse was approximately 51014
VG=kg body weight; whereas the vector dose in the dogs was
no more than 1013 VG=kg body weight). Quantitative vector
DNA PCR results showed that the highest vector copy num-
ber in the AAV-injected dog limbs was 1.55 copies per
nucleus. On the other hand, vector copy numbers in some
muscles were as low as<0.1 copy per nucleus; the vector copy
FIG. 3. Detection of cMPRO–Fc protein expression. (a) Western blot analysis demonstrates the expected band from the
treated muscles of dog Ramone. (b) Immunofluorescence staining against dog MPRO indicates that cMPRO–Fc is expressed
in treated muscle. Scale bar: 100 mm. (c) ELISA analysis of injected dog (Ramone) serum. cMPRO–Fc was detected from serum
1 week after vector delivery (900 pg=ml). Four weeks after vector delivery, the expression serum level of cMPRO–Fc in
Ramone was reduced to about 600 pg=ml.
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numbers in skeletal muscles of adult mice were in the
neighborhood of 10 copies per nucleus after neonatal AAV8
injection (Wang et al., 2005). This could account, in part, for the
less robust enhancement of muscle growth in dogs than in
mice. Apparently, room exists for technical improvement,
such as better injection techniques, higher vector doses, and
choice of more efficient AAV serotypes. Indeed, AAV9 vector
has been shown to be more robust than AAV8 in both small
and large animals in systemic delivery (Inagaki et al., 2006;
Pacak et al., 2006). Preliminary data of Duan and coworkers
FIG. 4. Enhancement of muscle
growth by AAV8-cMPRO-Fc in injected
dog hind limbs. (a) Histological exam-
ination of muscle sections. It is notable
that treated muscle displayed larger
muscle fiber sizes without mononu-
clear cell infiltration. Scale bars: 100mm.
(b) Semiquantitative analysis of muscle
fiber sizes, using MetaMorph software.
In detail, 8- to 10-mm cryo-thin sections
of biopsied muscles (from dog Ramone)
were subjected to immunofluorescence
staining against the laminin g chain to
display circumferences of the myofi-
bers. Pictures were taken and radii of
the myofibers were analyzed with
MetaMorph software, using a minimum
of 300 myofibers from each muscle. (c)
MRI volumetric analysis indicated that
muscle sizes were increased in some
muscles of the vector-perfused leg,
compared with the contralateral non-
perfused control leg. Data were ob-
tained from five consecutive 1-mm
cross-section segments.
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(Yue et al., 2008) and our own data obtained in dogs support
this notion. As mentioned in Results, we did not detect
myofiber size increase in the vastus lateralis muscle of dog
Ramone, although vector DNA copy number, mRNA, and
cMPRO–Fc protein expression were similar in this muscle as
in the gastrocnemius and biceps femoris muscles, both of
which showed growth enhancement. The weaker growth
enhancement in certain muscles might be due to a higher
threshold for myostatin inhibition in those muscle groups,
although this phenomenon was not apparent in mice. Inter-
estingly, homozygous myostatin gene mutant whippet dogs
are more muscular than their heterozygous littermates
(Mosher et al., 2007). This indicates that growth enhancement
through myostatin inhibition in dogs is dose dependent, as in
mice. It remains to be investigated whether in dogs the dys-
trophic muscles are also more responsive than the normal
muscles to myostatin inhibition as seen in our previous mouse
studies (Qiao et al., 2008).
We did not observe significant CD4þ or CD8þ T lympho-
cyte infiltration in AAV8-cMPRO-Fc-treated skeletal muscles
in this study. For example, the total CD4þ T cells in an entire
cross-sectional area of a muscle biopsy were less than 20 as
revealed by immunofluorescence staining (data not shown).
In contrast, Wang and coworkers reported that strong cellular
immune responses appeared on AAV2 and AAV6 vector
delivery into skeletal muscles of normal dogs (Wang et al.,
2007). Their study differed from ours in several ways, such as
in delivery route, AAV serotypes used, as well as transgenes
expressed. We believe those factors will affect the immune
response in dogs after delivery of AAV vector into skeletal
muscles, as other groups have also achieved successful
transgene expression and therapeutic effect in dogs without
immunosuppressant drugs ( Jiang et al., 2006; Koeberl et al.,
2008).
Dystrophin-deficient GRMD dogs show signs of pathology
similar to those of DMD patients and serve as a useful and
clinically relevant large animal model (Schatzberg et al., 1998;
Liu et al., 2004). Two of the major pathological hallmarks of
GRMD are muscle atrophy and fibrosis. Blockade of myos-
tatin could counter both by enhancing muscle growth and
inhibiting fibrosis (Li et al., 2008). There are several venues
to evaluate the therapeutic effects of myostatin blockade=
inhibition in GRMD dogs. One of them is the frequent ad-
ministration of a purified myostatin-blocking antibody. A
humanized antibody, MYO-029, has been used in clinical
trials and has shown safety (Wagner et al., 2008). However, at
present there is no caninized antibody available for studies in
dogs. Another way to test efficacy is to cross the GRMD dogs
with myostatin mutant whippet dogs (Mosher et al., 2007),
which show muscle hypertrophy. However, it will be time-
consuming to cross the two breeds. In addition, the influence
of myostatin mutation in this case will exert its effects from the
embryonic stage, which is not possible in a clinical setting for
DMD therapy. As a result, somatic gene delivery of myostatin
blockers or inhibitors in the GRMD dog remains a viable and
practical approach and, if successful, could be translated into
human clinical trials. In fact, several reports, including ours,
have shown that myostatin blockade is effective in amelio-
rating dystrophic pathology in mdx mice (Bogdanovich et al.,
2002, 2005; Wagner et al., 2002; Haidet et al., 2008; Nakatani
et al., 2008; Qiao et al., 2008). Further study in large animal
models, such as GRMD dogs, is well warranted.
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